Intel just had its worst day in years, and the reason is simple: it can't make enough chips. The stock dropped about 28% on Friday, wiping roughly $12 billion off the value of the government's 10% stake and dragging Nvidia down with it. Even after the crash, Intel is still up more than 70% for the year, so this is a pullback from a big run, not a collapse.
Why should you care? Because the AI boom is now squeezing the boring stuff. Demand for memory and components from AI data centers is driving PC prices up, and PC sales are getting hurt. If you're budgeting for new laptops or workstations this year, expect higher sticker prices and fewer deals.
The numbers are rough. Intel guided Q4 revenue to $15-16 billion against analyst expectations near $17 billion. Gross margin is expected to fall to 37%, and Intel expects no positive cash flow. The bright spot is data center revenue, which grew 78% year over year, but Intel says that business is capped until it adds fab capacity.
Watch the fabs. Arizona is operational, but the next Intel fab isn't expected online until 2028, which means the supply crunch isn't going away soon.
Anthropic is probably headed for junk territory. Blackstone, the anchor investor in a $63 billion deal to finance Anthropic's chips, now expects a double-B rating after the IPO. That's the top tier of speculative grade, and it's a clear step back from the investment-grade rating Blackstone had promised before 2027.
Why should you care? Because the people funding your AI tools are the ones paying this bill. Anthropic has been on a compute spending spree for the past year, and a junk rating means more expensive, harder-to-get money for the next round of data centers. If you build on Claude, pricing and rate limits are downstream of that math. Vendor stability is not a theoretical concern anymore.
The numbers: the $63 billion chip financing is the anchor. Anthropic filed to go public earlier this week, and the IPO is expected to ripple through the broader AI industry. Investors have been openly worried about the scale of the spending.
Watch the final rating when it lands after the listing. If it's really double-B, expect the lab to keep leaning on debt partners and push hard on revenue growth to offset the cost. Let's dive deeper…
In today's ContentBuffer update: